ES2621664T3 - Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico - Google Patents

Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Download PDF

Info

Publication number
ES2621664T3
ES2621664T3 ES12846895.6T ES12846895T ES2621664T3 ES 2621664 T3 ES2621664 T3 ES 2621664T3 ES 12846895 T ES12846895 T ES 12846895T ES 2621664 T3 ES2621664 T3 ES 2621664T3
Authority
ES
Spain
Prior art keywords
dihydroquinolin
cyclopropylamino
fluoroethyl
fluoro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12846895.6T
Other languages
English (en)
Spanish (es)
Inventor
Ichiro Araya
Akinori Goto
Wataru Minagawa
Keiko Funada
Muneki Nagao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2621664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2621664T3 publication Critical patent/ES2621664T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES12846895.6T 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Active ES2621664T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2011246209 2011-11-10
JP2012071739 2012-03-27
JP2012071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (ja) 2011-11-10 2012-11-09 ７－｛（３s、４s）－３－［（シクロプロピルアミノ)メチル］－４－フルオロピロリジン－1－イル｝－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１、４－ジヒドロキノリン－３－カルボン酸の結晶

Publications (1)

Publication Number Publication Date
ES2621664T3 true ES2621664T3 (es) 2017-07-04

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12846895.6T Active ES2621664T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Country Status (17)

Country Link
US (3) US9090587B2 (https=)
EP (2) EP3112359B1 (https=)
JP (4) JP5871948B2 (https=)
KR (2) KR102162208B1 (https=)
CN (2) CN103930414B (https=)
AU (1) AU2016273899B2 (https=)
BR (1) BR112014010765B1 (https=)
CA (1) CA2855022C (https=)
ES (2) ES2621664T3 (https=)
IN (1) IN2014DN03277A (https=)
MX (1) MX375073B (https=)
NZ (1) NZ623808A (https=)
RU (2) RU2615509C2 (https=)
SA (1) SA112330992B1 (https=)
SG (2) SG11201401817TA (https=)
TW (1) TWI547492B (https=)
WO (1) WO2013069297A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594418B2 (en) 2011-03-10 2026-04-07 Electrocore, Inc. Devices and methods for nerve stimulation
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
JP6349306B2 (ja) * 2013-04-25 2018-06-27 杏林製薬株式会社 錠剤
US9687453B2 (en) * 2013-04-25 2017-06-27 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
CA2910112C (en) 2013-04-25 2021-02-16 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US10154993B2 (en) * 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
EP3210608A4 (en) * 2014-10-23 2018-06-20 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
US20180042918A1 (en) * 2015-03-13 2018-02-15 Kyorin Pharmaceutical Co., Ltd. Respiratory infection treating agent
JP6031217B1 (ja) 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
WO2016195020A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
JP6031216B1 (ja) * 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
US20210137913A1 (en) 2017-06-16 2021-05-13 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
TW202415375A (zh) 2017-06-16 2024-04-16 日商杏林製藥股份有限公司 吸入性肺炎、肺化膿症或肺膿瘍之治療劑
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
JPWO2003076428A1 (ja) * 2002-03-08 2005-07-07 第一製薬株式会社 キノロンカルボン酸誘導体
WO2005026147A1 (ja) 2003-09-10 2005-03-24 Kyorin Pharmaceutical Co., Ltd. ７−（４−置換−３−シクロプロピルアミノメチル−１−ピロリジニル）キノロンカルボン酸誘導体
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
JP2016027045A (ja) 2016-02-18
KR20140098074A (ko) 2014-08-07
BR112014010765A2 (pt) 2017-06-13
CN104945375B (zh) 2017-07-04
RU2017109814A (ru) 2019-01-23
SG10201608167UA (en) 2016-11-29
CA2855022A1 (en) 2013-05-16
KR20190065456A (ko) 2019-06-11
EP2778159A4 (en) 2015-06-03
CA2855022C (en) 2019-05-07
JP5871948B2 (ja) 2016-03-01
EP3112359B1 (en) 2019-08-21
US20150284361A1 (en) 2015-10-08
ES2747303T3 (es) 2020-03-10
AU2016273899A1 (en) 2017-01-12
EP2778159B1 (en) 2017-03-01
JPWO2013069297A1 (ja) 2015-04-02
TWI547492B (zh) 2016-09-01
RU2017109814A3 (https=) 2020-04-08
CN103930414A (zh) 2014-07-16
RU2615509C2 (ru) 2017-04-05
JP2017160243A (ja) 2017-09-14
JP2018158949A (ja) 2018-10-11
CN104945375A (zh) 2015-09-30
AU2016273899B2 (en) 2017-07-27
US9328089B2 (en) 2016-05-03
MX375073B (es) 2025-03-06
WO2013069297A1 (ja) 2013-05-16
TW201332991A (zh) 2013-08-16
SG11201401817TA (en) 2014-08-28
AU2012337206A1 (en) 2014-05-22
US9090587B2 (en) 2015-07-28
JP6514069B2 (ja) 2019-05-15
NZ623808A (en) 2015-07-31
KR102162208B1 (ko) 2020-10-06
JP6349435B2 (ja) 2018-06-27
EP3112359A1 (en) 2017-01-04
US20140288310A1 (en) 2014-09-25
AU2012337206B2 (en) 2016-09-15
CN103930414B (zh) 2016-01-20
SA112330992B1 (ar) 2015-09-13
RU2014123567A (ru) 2015-12-20
USRE47785E1 (en) 2019-12-31
IN2014DN03277A (https=) 2015-05-22
EP2778159A1 (en) 2014-09-17
AU2012337206A8 (en) 2016-09-22
BR112014010765B1 (pt) 2020-07-14
JP6818719B2 (ja) 2021-01-20

Similar Documents

Publication Publication Date Title
ES2621664T3 (es) Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
ES2493940T3 (es) Una forma amorfa y una forma cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
AU2019234185B2 (en) Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
ES2565521T3 (es) Polimorfos de dasatinib y proceso para la preparación de los mismos
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
HRP20241723T1 (hr) Kristalni toluen solvat od (s)-afoksolanera
CA2970500C (en) Piperidine derivatives as hdac1/2 inhibitors
ES2613716T3 (es) Formas cristalinas de un derivado de purina
NZ598277A (en) Process for preparing azabicyclic compounds
Cheng et al. 7, 7′-diazaindirubin—a small molecule inhibitor of casein kinase 2 in vitro and in cells
HRP20180970T1 (hr) Policiklični lpa1 antagonist i njegove primjene
TW200463B (https=)
UA119243C2 (uk) Сполуки індолізину, спосіб їх одержання і фармацевтичні композиції, що їх містять
CO6700138A1 (es) Procedimiento de preparación de sal de l-arginina de perindoprilo
CN103709120B (zh) 一种盐酸阿考替胺三水合物的制备方法
RU2015117524A (ru) Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция
ES2543804T3 (es) Polimorfo B de Ibandronato
EP3131899A1 (en) Polymorphic forms of 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid and its disodium salt, process for their preparation and their use
ES2554933T3 (es) Procedimiento de síntesis y forma cristalina de clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida, así como la base libre asociada y las composiciones farmacéuticas que los contienen
CN103467466A (zh) 一种盐酸莫西沙星杂质的合成方法
AU2013385618A1 (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
SK50032014U1 (sk) Kryštalický dihydrát bilastínu
AR085171A1 (es) Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene
MD20120130A2 (en) Delta crystalline form of the L-arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
RU2011143166A (ru) Новые кристаллические формы адефовира дипивоксила и способы его получения